# BIH Senologie PD-L1 Status - Kerndatensatz Senologie v0.10.0

* [**Table of Contents**](toc.md)
* [**Artifacts Summary**](artifacts.md)
* **BIH Senologie PD-L1 Status**

## Resource Profile: BIH Senologie PD-L1 Status 

| | |
| :--- | :--- |
| *Official URL*:https://www.senologie.org/fhir/StructureDefinition/senologie-pdl1-status | *Version*:0.10.0 |
| Draft as of 2026-10-12 | *Computable Name*:Senologie_PDL1_Status |

 
PD-L1 Immunhistochemie-Befund für Mamma-Karzinom. Erbt TPS, CPS, ICS und TC-Score Slices vom MII MTB PD-L1 Profil. Klinisch relevant bei TNBC (Pembrolizumab-Indikation bei CPS >= 10, KEYNOTE-522). 

**Usages:**

* Use this Profile: [Senologie Meldungs-Bundle](StructureDefinition-senologie-meldungs-bundle.md)
* Examples for this Profile: [Observation/Fall10-PDL1-Status](Observation-Fall10-PDL1-Status.md), [Observation/Fall2-PDL1-Status](Observation-Fall2-PDL1-Status.md) and [Observation/Fall7-PDL1-Status](Observation-Fall7-PDL1-Status.md)

You can also check for [usages in the FHIR IG Statistics](https://packages2.fhir.org/xig/resource/kds-senologie|current/StructureDefinition/StructureDefinition-senologie-pdl1-status.json)

### Formal Views of Profile Content

 [Description of Profiles, Differentials, Snapshots, and their representations](http://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#structure-definitions). 

 

Other representations of profile: [CSV](../StructureDefinition-senologie-pdl1-status.csv), [Excel](../StructureDefinition-senologie-pdl1-status.xlsx), [Schematron](../StructureDefinition-senologie-pdl1-status.sch) 



## Resource Content

```json
{
  "resourceType" : "StructureDefinition",
  "id" : "senologie-pdl1-status",
  "meta" : {
    "extension" : [{
      "url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
      "valueCode" : "CC-BY-4.0"
    },
    {
      "extension" : [{
        "url" : "packageId",
        "valueId" : "kds-senologie"
      },
      {
        "url" : "version",
        "valueString" : "0.10.0"
      },
      {
        "url" : "uri",
        "valueUri" : "https://www.senologie.org/fhir"
      }],
      "url" : "http://hl7.org/fhir/StructureDefinition/package-source"
    }],
    "profile" : ["http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareablestructuredefinition",
    "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishablestructuredefinition"]
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode" : "shareable"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode" : "publishable"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-usage",
    "valueMarkdown" : "Use this profile as the technical FHIR representation of the corresponding element group of the Senologie core dataset logical model. The profile constrains a base FHIR resource for the documentation of breast cancer care by specifying how elements are used, which elements are required, and which extensions and terminology bindings apply. Implementers should produce and consume resource instances that conform to this profile when exchanging Senologie core dataset data."
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
    "valueCodeableConcept" : {
      "coding" : [{
        "system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
        "version" : "3.0.0",
        "code" : "package",
        "display" : "Package"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic",
    "valueCodeableConcept" : {
      "coding" : [{
        "system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
        "code" : "C4872",
        "display" : "Breast Carcinoma"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
    "valueContactDetail" : {
      "name" : "Berlin Institute of Health at Charité (BIH)",
      "telecom" : [{
        "system" : "email",
        "value" : "thomas.debertshaeuser@charite.de"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor",
    "valueContactDetail" : {
      "name" : "Berlin Institute of Health at Charité (BIH)",
      "telecom" : [{
        "system" : "url",
        "value" : "https://www.bihealth.org"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
    "valueContactDetail" : {
      "name" : "Deutsche Gesellschaft für Senologie (DGS)",
      "telecom" : [{
        "system" : "url",
        "value" : "https://www.senologie.org"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
    "valueContactDetail" : {
      "name" : "Deutsche Gesellschaft für Senologie (DGS)",
      "telecom" : [{
        "system" : "url",
        "value" : "https://www.senologie.org"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
    "valueContactDetail" : {
      "name" : "Deutsche Gesellschaft für Senologie (DGS)",
      "telecom" : [{
        "system" : "url",
        "value" : "https://www.senologie.org"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
    "valueContactDetail" : {
      "name" : "Deutsche Gesellschaft für Senologie (DGS)",
      "telecom" : [{
        "system" : "url",
        "value" : "https://www.senologie.org"
      }]
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
    "valueCoding" : {
      "system" : "http://hl7.org/fhir/version-algorithm",
      "code" : "semver",
      "display" : "SemVer"
    }
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
    "valueDate" : "2026-09-15"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
    "valuePeriod" : {
      "start" : "2027"
    }
  }],
  "url" : "https://www.senologie.org/fhir/StructureDefinition/senologie-pdl1-status",
  "version" : "0.10.0",
  "name" : "Senologie_PDL1_Status",
  "title" : "BIH Senologie PD-L1 Status",
  "status" : "draft",
  "experimental" : false,
  "date" : "2026-10-12",
  "publisher" : "Berlin Institute of Health at Charité (BIH)",
  "_publisher" : {
    "extension" : [{
      "extension" : [{
        "url" : "lang",
        "valueCode" : "en"
      },
      {
        "url" : "content",
        "valueString" : "Berlin Institute of Health at Charité (BIH)"
      }],
      "url" : "http://hl7.org/fhir/StructureDefinition/translation"
    }]
  },
  "contact" : [{
    "name" : "Berlin Institute of Health at Charité (BIH)",
    "telecom" : [{
      "system" : "url",
      "value" : "https://www.bihealth.org"
    }]
  }],
  "description" : "PD-L1 Immunhistochemie-Befund für Mamma-Karzinom. Erbt TPS, CPS, ICS und TC-Score Slices vom MII MTB PD-L1 Profil. Klinisch relevant bei TNBC (Pembrolizumab-Indikation bei CPS >= 10, KEYNOTE-522).",
  "fhirVersion" : "4.0.1",
  "mapping" : [{
    "identity" : "lm",
    "uri" : "https://www.senologie.org/fhir/StructureDefinition/LogicalModelSenologie",
    "name" : "BIH LM Senologie",
    "comment" : "Bezugselement im Logischen Modell: Pathologie.BefundInvasiv.Biomarker"
  },
  {
    "identity" : "workflow",
    "uri" : "http://hl7.org/fhir/workflow",
    "name" : "Workflow Pattern"
  },
  {
    "identity" : "sct-concept",
    "uri" : "http://snomed.info/conceptdomain",
    "name" : "SNOMED CT Concept Domain Binding"
  },
  {
    "identity" : "v2",
    "uri" : "http://hl7.org/v2",
    "name" : "HL7 v2 Mapping"
  },
  {
    "identity" : "w5",
    "uri" : "http://hl7.org/fhir/fivews",
    "name" : "FiveWs Pattern Mapping"
  },
  {
    "identity" : "sct-attr",
    "uri" : "http://snomed.org/attributebinding",
    "name" : "SNOMED CT Attribute Binding"
  }],
  "kind" : "resource",
  "abstract" : false,
  "type" : "Observation",
  "baseDefinition" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry-pdl1",
  "derivation" : "constraint",
  "differential" : {
    "element" : [{
      "id" : "Observation.status",
      "path" : "Observation.status",
      "mustSupport" : true
    },
    {
      "id" : "Observation.code.text",
      "path" : "Observation.code.text",
      "short" : "PD-L1 Immunhistochemie"
    },
    {
      "id" : "Observation.subject",
      "path" : "Observation.subject",
      "type" : [{
        "code" : "Reference",
        "targetProfile" : ["http://hl7.org/fhir/StructureDefinition/Patient"]
      }]
    },
    {
      "id" : "Observation.effective[x]",
      "path" : "Observation.effective[x]",
      "short" : "Datum der IHC-Untersuchung"
    },
    {
      "id" : "Observation.method",
      "path" : "Observation.method",
      "short" : "IHC-Klon / Assay (z.B. SP142, 22C3, SP263)",
      "comment" : "Der verwendete Antikörperklon ist klinisch relevant: SP142 (Ventana) für Atezolizumab, 22C3 (Dako) für Pembrolizumab, SP263 (Ventana) für Durvalumab.",
      "mustSupport" : true
    },
    {
      "id" : "Observation.specimen",
      "path" : "Observation.specimen",
      "short" : "Pathologisches Präparat (Stanzbiopsie / OP-Resektat)"
    },
    {
      "id" : "Observation.component:tps-score",
      "path" : "Observation.component",
      "sliceName" : "tps-score",
      "short" : "Tumor Proportion Score (TPS)"
    },
    {
      "id" : "Observation.component:cps-score",
      "path" : "Observation.component",
      "sliceName" : "cps-score",
      "short" : "Combined Positive Score (CPS)",
      "comment" : "Primärer Score für Pembrolizumab-Indikation bei TNBC. CPS >= 10 ist Schwellenwert (KEYNOTE-522)."
    },
    {
      "id" : "Observation.component:ics-score",
      "path" : "Observation.component",
      "sliceName" : "ics-score",
      "short" : "Immune Cell Score (ICS)",
      "comment" : "Relevant für Atezolizumab-Indikation (IMpassion130). IC >= 1% ist Schwellenwert."
    }]
  }
}

```
